Blueprint’s Ayvakit fails to best Bayer’s Stivarga
The firm said based on the data it would not be pursuing further development of the drug in GIST beyond its approved indication
Read More
Tag: Ayvakit
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
